Delcath Systems (NASDAQ:DCTH) Announces Quarterly Earnings Results

Delcath Systems (NASDAQ:DCTH) issued its earnings results on Thursday. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.07, FiscalAI reports. The business had revenue of $24.99 million during the quarter, compared to analyst estimates of $23.51 million. Delcath Systems had a return on equity of 0.51% and a net margin of 0.62%.

Here are the key takeaways from Delcath Systems’ conference call:

• Q1 operational momentum: the company activated 4 centers, reported record new patient starts, has 29 REMS‑certified sites and is modifying its activation goal to 37 centers by year‑end (40 by Q1 2027), reflecting broad commercial interest.
• Strong topline and guidance: Q1 revenue rose to $25.0M (vs $19.8M LY), ending cash of $89.3M, and management reiterated at least $100M revenue for 2026 with expected positive adjusted EBITDA for the remainder of the year.
• Clinical programs progressing but paced slowly: the metastatic CRC trial has 13 active screening sites with 7 patients enrolled (target 26 sites by year‑end; interim readout late 2027) and the metastatic breast program has 4 sites active with a target of 15 by late 2026, so readouts remain long‑dated and enrollment is ramping.
• CHOPIN data driving adoption: publication of the CHOPIN results in The Lancet Oncology (combination HEPZATO + immunotherapy showing ~76% response and survival separation) is cited as a key factor changing prescribing patterns and motivating many new sites to adopt a CHOPIN‑like protocol.

Delcath Systems Stock Up 2.1%

NASDAQ:DCTH traded up $0.24 on Friday, hitting $11.48. The stock had a trading volume of 569,665 shares, compared to its average volume of 339,366. Delcath Systems has a 52-week low of $8.12 and a 52-week high of $18.23. The stock has a market cap of $395.60 million, a price-to-earnings ratio of 1,148.00 and a beta of 0.54. The business’s 50-day simple moving average is $9.86 and its two-hundred day simple moving average is $9.82.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Franklin Resources Inc. bought a new stake in Delcath Systems in the 3rd quarter worth approximately $206,000. Corsair Capital Management L.P. bought a new position in shares of Delcath Systems during the 4th quarter valued at approximately $202,000. Two Sigma Investments LP purchased a new position in Delcath Systems during the 3rd quarter valued at $194,000. Bayesian Capital Management LP purchased a new position in Delcath Systems during the 2nd quarter valued at $181,000. Finally, Intech Investment Management LLC boosted its holdings in Delcath Systems by 13.1% during the 4th quarter. Intech Investment Management LLC now owns 17,595 shares of the company’s stock valued at $178,000 after acquiring an additional 2,035 shares during the period. 61.12% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Evercore set a $27.00 price target on shares of Delcath Systems in a report on Thursday, February 26th. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Delcath Systems in a report on Friday, January 9th. BTIG Research reduced their price target on Delcath Systems from $23.00 to $19.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Finally, Wall Street Zen cut Delcath Systems from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $22.50.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.